Thalidomide alone or in combination: results in refractory patients

Published: June 5, 2009
Abstract Views: 217
PDF: 347
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Thalidomide was first marketed in the 1950s for the treatment of pregnancy-related morning sickness and later as a sedative, but was withdrawn because of serious adverse events in pregnant women including teratogenicity and dysmelia.1 Interest in the drug resurfaced in the 1990s because of its antiangiogenic and immunomodulatory effects.2 Recently thalidomide has been used to treat multiple myeloma (MM) either alone or in combination with other therapies. This review summarizes study results of thalidomide treatment in patients who have not benefited from conventional therapy.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

San Miguel, J. F. (2009). Thalidomide alone or in combination: results in refractory patients. Hematology Meeting Reports (formerly Haematologica Reports), 1(11). https://doi.org/10.4081/hmr.v1i11.350